SEMA3B is associated with disease activity and infliximab response in IBD patients but does not contribute to the development of intestinal inflammation in vivo

Laura Arosa(Instituto de Investigación Sanitaria de Santiago), Javier Conde-Aranda(Instituto de Investigación Sanitaria de Santiago)
Frontiers in Immunology
February 4, 2026
Cited by 0


Related Papers

No related papers found

Powered by citation graph analysis